Skip to main content
SpringerLink
Log in

Sevirumab

Protovir®, MSL 109, EV2 7, SDZ MSL 109

  • Section 1: Cytomegalovirus Retiniti
  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Drobyski WR, Gottlieb M, Carrigan D, et al. Phase I study of safety and pharmacokinetics of a human anticytomegalovirus monoclonal antibody in allogeneic bone marrow transplant recipients. Transplantation 1991 Jun; 51: 1190–6

    Article  PubMed  CAS  Google Scholar 

  2. Nokta MA, Tolpin MD, Nadler PI, et al. Human monoclonal anti cytomegalovirus antibody (MSL-109): enhancement of in vitro ganciclovir induced inhibition of CMV replication. Antiviral Res 1991 Apr; 15 Suppl. 1: 77

    Google Scholar 

  3. Protein Design Labs announces results from phase II study of PROTOVIR (Rm) in bone marrow transplantation. PR Newswire [online]. 2 Jul 1997. URL: http://www.newspage.com [Accessed 1997 Jul 14]

  4. Dunkel EC, Siegel ML, Brooks J, et al. MSL-109 therapy of human cytomegalovirus-induced chorioretinitis in the rabbit. Antiviral Res 1991 Apr; 15 Suppl. 1: 121

    Google Scholar 

  5. Lakeman F, Blevins C, Whitley R, et al. In vitro neutralization of cytomegalovirus strains by a human monoclonal antibody, MSL-109. Antiviral Res 1991 Apr; 15 Suppl. 1: 77

    Article  Google Scholar 

  6. Nokta M, Tolpin M, Nadler P, et al. Combination effects of a human monoclonal anti cytomegalovirus (CMV) antibody (MSL 109) and foscarnet or ganciclovir on CMV replication in vitro. Antiviral Res 1993; 20 Suppl. 1: 110

    Google Scholar 

  7. Tolpin M, Pollard R, Tierney M, et al. Combination therapy of cytomegalovirus retinitis with a human monoclonal anti-CMV antibody (SDZ MSL 109) and either ganciclovir or foscarnet. 9th International Conference on AIDS; 1993 Jun 6–11; Berlin, I: 54

    Google Scholar 

  8. Protein Design Labs announces halt to one of three ongoing clinical trials in CMV disease [media release]. PR Newswire 1996 Aug 14

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sevirumab. Drugs R&D 2, 315–317 (1999). https://doi.org/10.2165/00126839-199902050-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-199902050-00008

Keywords

Search

Navigation